Roche strengthens its pipeline by acquiring 89bio and its promising MASH treatment, Pegozafermin, enhancing options for metabolic disease therapies.

Rob DeWig, Vice President of Healthcare Sales, Inmar, touches on the impact of Inmar and Premier's expanded agreement on the broader healthcare and pharmacy ecosystems.

With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s formula for navigating the new age of innovation, where running from risk is not an option.

In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, Merck and Daiichi Sankyo’s breakthrough therapy designation for R-DXd in ovarian cancer, and Novo Nordisk’s EU approval of Rybelsus for reducing cardiovascular risk.

As drugmakers navigate an increasingly complex terrain of scientific and digital influence, the ability to accurately identify and understand both key and digital opinion leaders is vital for effective engagement.

FDA warns major pharmaceutical companies to improve transparency in drug advertising, addressing misleading claims and enforcing stricter regulations.

VarmX partners with CSL to advance VMX-C001, a groundbreaking treatment for patients on FXa DOACs, enhancing surgical outcomes and patient care.

Eli Lilly's Orforglipron shows superior results in glycemic control and weight loss compared to oral semaglutide in recent clinical trials.

The new Goochland County facility will serve as Lilly’s first fully integrated API and drug product site, focusing on antibody-drug conjugates, while creating thousands of jobs and strengthening domestic supply chains.

Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition journey.

A Harvard Business School Healthcare Alumni Q&A with Professor Eric Mazur of Harvard University.

Ryan Quigley, CEO of Inizio, discusses how his experience as Chief Operating Officer shaped his journey to CEO.

In today’s Pharmaceutical Executive Daily, we cover AbbVie’s stock jump following a Rinvoq litigation settlement, new insights into the ROI of specialty pharmacy adherence programs, and a closer look at what true innovation in PBM management entails.

AllRock Bio secures $50 million to advance Roc-101, a promising treatment for pulmonary hypertension, aiming to transform patient care.

Useful tips and parallels for staying in the game following a complete response letter.

The new members include individuals who have ties to fringe medical communities.

Novo Nordisk's Rybelsus gains EU approval for cardiovascular benefits, enhancing treatment options for type 2 diabetes and improving patient outcomes.

R-DXd has previously shown promising clinical results in platinum-resistant ovarian, peritoneal, and fallopian tube cancers.

Eli Lilly's Orforglipron may become the first drug fast-tracked under the FDA's new program, promising quicker access for weight loss treatment.

Ways biopharma organizations and media brands can leverage coverage opportunities to help achieve respective audience goals and missions.

The quest to align cost with care, enhance data visibility, and shed the dependence on outdated revenue streams.

Updates to its policies have made FDA’s CRLs a key talking point.

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s return-to-office mandate from its CEO, the evolving COVID-19 vaccine landscape in 2025, and Capsida’s decision to halt a gene therapy trial following a patient death.

The Aligos Therapeutics chairman, president, and CEO discusses his journey to building his own company and bringing an experienced team along with him.

AstraZeneca pauses its £271 million Cambridge investment, reflecting growing concerns over the U.K.'s life sciences sector and government support.